Genelux Corporation - Common Stock (GNLX)
2.4400
-0.0800 (-3.17%)
NASDAQ· Last Trade: Sep 4th, 9:33 PM EDT

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock moved upwards by
Via Benzinga · September 4, 2026
Stay updated with the stocks that are on the move in today's after-hours session.chartmill.com
Via Chartmill · September 4, 2026
These stocks are gapping in today's sessionchartmill.com
Via Chartmill · January 8, 2026
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
Via Chartmill · January 8, 2026

GNLX stock results show that Genelux beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024

Genelux shares are trading lower by 40.7% during Friday's session. The company announced the pricing of an underwritten offering of 6.875 million shares.
Via Benzinga · May 24, 2024
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of capital as two prominent players, Monte Rosa Therapeutics (NASDAQ: GLUE) and Genelux Corporation (NASDAQ: GNLX), launched public offerings. These moves signal
Via MarketMinute · January 7, 2026
Via Benzinga · November 6, 2025
Via Benzinga · October 23, 2025
Via Benzinga · July 21, 2025

Via Benzinga · November 15, 2024

Via Benzinga · October 22, 2024

Via Benzinga · September 4, 2024

Via Benzinga · May 24, 2024

Via Benzinga · May 24, 2024





